Schedule of Restricted Stock Award Activity (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	975,000	[1]
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares	$ 3.05	[1]
Number of Stock Options, Granted | shares
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Stock Options, Vested | shares	(100,000)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 3.10
Number of Stock Options, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Stock Options Outstanding, Ending Balance | shares	875,000	[1]
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares	$ 3.04	[1]
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	2,091,420	[2]
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares	$ 11.44	[2]
Number of Stock Options, Granted | shares
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Stock Options, Vested | shares	(219,320)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 11.27
Number of Stock Options, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Stock Options Outstanding, Ending Balance | shares	1,872,100	[2]
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares	$ 11.46	[2]

[1] The unvested restricted stock awards presented in the table above, are inclusive of 100,000 restricted stock awards granted outside the PAVmed 2014 Equity Plan as of December 31, 2022. These 100,000 restricted stock awards were fully vested during the period ended March 31, 2023.

[2] The unvested restricted stock awards presented in the table above, are inclusive of 50,000 restricted stock awards granted outside the Lucid Diagnostics 2018 Equity Plan as of December 31, 2022. These 50,000 restricted stock awards were fully vested during the period ended March 31, 2023.